Sales Growth YoY (Last 12 Months): ImmunityBio, Inc. (IBRX)

Public company logo of NantKwest (IBRX)

ImmunityBio, Inc. (IBRX) is implementing AI for molecule design and automating drug synthesis. The LTM sales growth YoY metric demonstrates the current trend, where the 120.80 level indicates the parameter's status. Development relies on a strong scientific staff and large-scale R&D investments, while the commercial success of Anktiva in bladder cancer therapy is actively driving revenue growth.

ImmunityBio (IBRX) Revenue Growth YoY (Last 12 Months): for the period 02/11/2024 - 11/15/2026

ImmunityBio (IBRX) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price NantKwest|IBRX - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization ImmunityBio Inc|IBRX - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share ImmunityBio|IBRX - Company Net Assets|Market Value to Equity Ratio immunitybio.com|IBRX - Cumulative Company Assets
- debt level and financial liquidity data:
Aggregate Debt to Capital ImmunityBio, Inc.|IBRX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital ImmunityBio|IBRX - Company Aggregate Debts|Debts to Book Value ImmunityBio Inc|IBRX - Company Long-Term Debt|Company Short-Term Loans and Borrowings ImmunityBio|Quick Ratio immunitybio.com
- earnings and market multiples details:
IBRX - Company Net Income|Forward Earnings ImmunityBio, Inc.|IBRX - Price to Earnings Ratio|Projected Price to Earnings Ratio ImmunityBio, Inc.|IBRX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio ImmunityBio Inc|IBRX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months ImmunityBio|IBRX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months immunitybio.com|IBRX - Net earnings per share growth this year|Earnings growth forecast for next year ImmunityBio, Inc.
- sales and revenue indicators:
IBRX - Company Revenue|Company Revenue Forecast ImmunityBio Corp|IBRX - P/S Multiple|Market Cap to Expected Sales Ratio ImmunityBio Corp|IBRX - Revenue Growth YoY (Last 12 Months)
Summary company analytics:ImmunityBio, Inc.
Product sample of immunitybio.com

Year-over-year sales growth (TTM) measures revenue dynamics over a rolling twelve-month period, neutralizing quarterly volatility to assess actual business expansion. This metric allows an investor to differentiate sustainable organic growth from speculative overheating of the asset's value. By analyzing the trend of annual sales volume changes (LTM), one can evaluate the efficiency of scaling operational activities. For ImmunityBio, Inc. (IBRX), this reflects a transition toward autonomy through the development of in-house capacities and a reduction in reliance on external laboratories.

Competitors of ImmunityBio, Inc. (IBRX)

Sales Growth YoY (TTM) Immunocore Corp IMCR|JANX - Sales Growth YoY (Last Twelve Months)|RCUS (arcusbio.com) - Sales Growth YoY (Last 12 Months)|Zymeworks Biopharmaceuticals (ZYME) - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Revenue Growth Tango Pharma (TNGX)|Revenue Growth YoY (Last 12 Months) IOVA|IMTX - Revenue Growth Rate YoY (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) XNCR (Xencor Corp)|Revenue Change YoY (Last 12 Months) CMPX|Sales Growth YoY (TTM) REPL (Replimune)|Revenue Dynamics YoY (Last Twelve Months) LYEL|innate-pharma.com - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Pyxis Oncology|Compugen Limited (CGEN) - Sales Growth YoY (Last Twelve Months)|IO Biotech, Inc. - Revenue Dynamics YoY (Last Twelve Months)|STRO (sutrobio.com) - Sales Growth YoY (TTM)|Sales Growth YoY (TTM) MiNK Therapeutics Inc.|Sales Growth YoY (Last Twelve Months) werewolftx.com (HOWL)|IMMX: Trailing Twelve Months Sales Growth|alxoncology.com - Revenue Growth YoY (Last 12 Months)|CUE - Revenue Growth YoY (Last 12 Months)|PDSB - Sales Growth YoY (Last Twelve Months)|Annual Revenue Growth (Last Twelve Months) Sonnet BioTherapeutics Holdings SONN|MAIA: Sales Growth YoY (TTM)|LIMN - Annual Revenue Growth (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) LVTX|Sales Growth YoY (Last 12 Months) NXTC (NextCure)|Sales Growth YoY (Last Twelve Months) leaptx.com (LPTX)|INTS - Trailing Twelve Months Revenue Growth|Sales Growth YoY (TTM) SNSE (Sensei Biotherapeutics, Inc.)|Annual Revenue Growth (Last Twelve Months) Theriva Biologics, Inc. (TOVX)|GRTS: Revenue Growth YoY (Last 12 Months)|Annual Revenue Growth (Last Twelve Months) kinetabio.com KA|NEXI (neximmune.com) - Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth Turnstone Biologics Corporation (TSBX)|Revenue Growth YoY (Last 12 Months) VCNX|HARP: Revenue Dynamics YoY (Last Twelve Months)